4197.TWO Visgeneer
- Market cap
- TWD 222M
- P/E
- -
- P/B
- 1.26x
- ROE
- 2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4197.TWO undervalued?
Graham numberThe Graham number of Visgeneer cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Visgeneer fundamental analysis
No fundamental analysis for Visgeneer yet.
Visgeneer stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Visgeneer
Visgeneer Inc. engages in the provision of health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cream, day cream, wrinkle cream, repairing cream, whitening cre…
Full company profileVisgeneer financial statements
Visgeneer annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 163M | 158M | 143M | 152M | 176M | 165M | 158M | 148M | 116M | 179M |
| Gross Profit | 68.8M | 39.3M | 38.3M | 37.4M | 62.2M | 67.3M | 67.3M | 67.5M | 53.3M | 68.4M |
| Operating Income | 2.59M | -24.0M | -33.5M | -30.3M | 256K | 3.60M | 15.2M | 3.99M | -20.5M | -5.41M |
| EBITDA | - | -9.26M | -9.01M | -10.5M | 20.7M | 19.2M | 34.4M | 21.2M | -804K | 20.3M |
| Net Income | 381K | -30.7M | -31.9M | -31.8M | 603K | 820K | 12.3M | -19.6M | -17.7M | 5.25M |
| EPS | - | -1.02 | -1.06 | -1.05 | 0.02 | 0.03 | 0.41 | -0.65 | -0.59 | 0.17 |
| Balance Sheet | ||||||||||
| Total Assets | 519M | 548M | 451M | 481M | 462M | 427M | 487M | 397M | 332M | 335M |
| Total Liabilities | 208M | 267M | 202M | 263M | 244M | 208M | 256M | 186M | 138M | 136M |
| Shareholders' Equity | 312M | 281M | 249M | 217M | 218M | 219M | 231M | 212M | 194M | 199M |
| Cash & Short-term Investments | 150M | 180M | 111M | 153M | 74.4M | 93.9M | 185M | 127M | 70.4M | 69.3M |
| Total Debt | - | - | - | 230M | 212M | 181M | 231M | 159M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 31.5M | -23.6M | -2.60M | -11.7M | 7.57M | 12.3M | 43.5M | 13.2M | -10.2M | 13.4M |
| Capital Expenditure | 12.5M | 4.82M | 2.78M | 1.48M | 22.1M | 7.89M | 1.69M | 585K | 3.80M | 5.38M |
| Free Cash Flow | - | -30.5M | -5.42M | -13.2M | -14.5M | 4.45M | 41.9M | 12.6M | -14.0M | 7.98M |
| Ratios | ||||||||||
| ROE | 0.1% | -10.9% | -12.8% | -14.6% | 0.3% | 0.4% | 5.3% | -9.3% | -9.1% | 2.6% |
| ROA | 0.1% | -5.6% | -7.1% | -6.6% | 0.1% | 0.2% | 2.5% | -4.9% | -5.3% | 1.6% |
| Net Profit Margin | 0.2% | -19.5% | -22.4% | -20.9% | 0.3% | 0.5% | 7.8% | -13.2% | -15.3% | 2.9% |
| Debt to Equity | - | - | - | 1.06x | 0.97x | 0.83x | 1.00x | 0.75x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Visgeneer dividends
Visgeneer has not paid dividends in the last 10 fiscal years.
Last stock split: 1050:1000 on Jul 12, 2016.
Who owns Visgeneer
Ownership data of Visgeneer is not available yet.
Visgeneer company profile
- Company name
- Visgeneer
- Ticker
- 4197.TWO
- ISIN
- TW0004197009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 335, Zhonghua Road, Hsinchu City, Taiwan, 30094
- Phone
- 886 3 5181 918
- Website
- visgeneer.com.tw
About Visgeneer
Visgeneer Inc. engages in the provision of health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cream, day cream, wrinkle cream, repairing cream, whitening cream, exfoliating cream, toner, and lotions; functional essences; body lotion and spa clay mask; physical blocker, chemical blocker, and comprehensive sun protection; face wash, wash cream, cleaning cleansing mousse, cleaning cleansing gel, shampoo, and body wash; hand cream, knee cream, foot mask, hand mask, and glucosamine cream; anti-acne cream, female private cleaning lotion, skin care, skin capsules, and hair capsules; and customized skin care products. In addition, the company offers eBmonitor Blood Monitoring System, CoreSence Skincare, BOWIL Skincare, angera, ZeaSight EU Patent Zeaxanthin, and Cancer Gene Diagnostics. Visgeneer Inc. was founded in 2005 and is based in Hsinchu City, Taiwan.
Visgeneer management
2- Kengshuo DaiChairman of the Board & GM
- Jiazhen ZhangAccounting Manager